Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.4 USD | +0.55% | -2.31% | -11.77% |
Financials (USD)
Sales 2024 * | 59.96B | Sales 2025 * | 62.57B | Capitalization | 144B |
---|---|---|---|---|---|
Net income 2024 * | 6.75B | Net income 2025 * | 9.29B | EV / Sales 2024 * | 3.18 x |
Net Debt 2024 * | 47.04B | Net Debt 2025 * | 41.91B | EV / Sales 2025 * | 2.97 x |
P/E ratio 2024 * |
18.7
x | P/E ratio 2025 * |
13.6
x | Employees | 88,000 |
Yield 2024 * |
6.68% | Yield 2025 * |
6.85% | Free-Float | 59.09% |
Latest transcript on Pfizer, Inc.
1 day | +0.93% | ||
1 week | -2.31% | ||
Current month | -8.47% | ||
1 month | -7.94% | ||
3 months | -7.54% | ||
6 months | -18.49% | ||
Current year | -11.77% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.74% | 215 M€ | +10.68% | - | |
9.37% | 18 M€ | +3.79% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 25.4 | +0.55% | 46,526,457 |
24-04-25 | 25.26 | -3.84% | 47,661,411 |
24-04-24 | 26.27 | -0.19% | 24,547,780 |
24-04-23 | 26.32 | +0.23% | 24,297,821 |
24-04-22 | 26.26 | +1.00% | 35,678,657 |
Delayed Quote Nyse, April 26, 2024 at 04:01 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.77% | 144B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PFE Stock